Several PI3K/Akt/mTOR inhibitors, such as idelalisib and copanlisib, have received approval from the FDA and are undergoing clinical testing.92 Everolimus, an mTOR inhibitor, demonstrated potential benefits in phase II trials for advanced GC93,94 but did not significantly improve OS in subsequent phase III trials.95 In a recent study by Chen et al.,96 the PI3K/mTOR dual inhibitor BEZ235 exhibited greater therapeutic efficacy than everolimus or the MEK inhibitor AZD6244 in paclitaxel-resistant GC cells. Here, PIK3CA is linked to gastric cancer.